Bioline RX Ltd (NASDAQ:BLRX) Dealt heart Drug Blow

960

Dallas, Texas 07/28/2015 (Financialstrend) – Bioline RX Ltd (NASDAQ:BLRX) felt the wrath of the street after announcing that its injectable heart drug failed a key clinical study. The stock shed more than 15% in market value as it became clear that the company was far off from receiving the much-needed approval for the drug.  The Israeli-based company had partnered Bellerophon Therapeutics Inc (NASDAQ:BLPH) to develop the treatment.

 Minimal Approval Chances

 A point of concern at the moment is the fact that Bioline RX Ltd (NASDAQ:BLRX) had invested over $10 million on the trial. The study carried out on 303 patients on different clinical sites failed to show any difference compared to patients who were administered with a placebo. Failure of the key clinical study jeopardizes any chances of the device getting the much-needed approval in Europe.

Despite the disappointment, Bioline RX Ltd (NASDAQ:BLRX) maintains its true value depends on its ability to continue advancing a deep in-house pipeline of mid-late stage assets. The company’s CEO, Dr. Kinneret Savitsky expects the ongoing collaboration with Novartis AG (ADR) (NYSE:NVS) in expanding the BL-8040 oncology platform to offset the disappointments on the heart disease drug.

Minimal Long-term Impact

 The outcome of the clinical study should have minimal impact on Bioline RX Ltd (NASDAQ:BLRX) business GOING forward according to the executive. The company has already reported positive safety efficacy results on Phase 1 study of BL-8040 seen as a novel stem cell mobilization treatment for transplantation

Bioline RX Ltd (NASDAQ:BLRX) plans to meet with the Federal Drug Administration to sort out the modalities on how the next steps in the clinical development program will be carried out. BL-1040 is an investigational implantable medical device being studied for the treatment of heart failure. Bioline RX Ltd (NASDAQ:BLRX) had licensed the device to Bellerophon in 2009 and has until now received $17 million as part of an ongoing licensing agreement.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.